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Summary: 1 8
The SORL1 gene encodes for the protein SorLA, a sorting receptor involved in 1 9
retromer-related endosomal traffic. Many SORL1 genetic variants increase Alzheimer's 2 0 disease (AD) risk, and rare loss-of-function truncation mutations have been found to be 2 1 causal of late-onset AD. SORL1 is expressed in neurons and glia of the central nervous 2 2 system and loss of SORL1 has been reported in AD tissue. To model the causal loss-of-2 3 function mutations, we used CRISPR/Cas9 technology to deplete SORL1 in human 2 4
induced pluripotent stem cells (hiPSCs) to test the hypothesis that loss of SORL1 2 5 contributes to AD pathogenesis by leading to endosome dysfunction. We report that 2 6 loss of SORL1 in hiPSC-derived neurons leads to early endosome enlargement, a 2 7 cellular phenotype that is indicative of 'traffic jams' and is now considered a hallmark 2 8 cytopathology AD. We validate defects in neuronal endosomal traffic by showing 2 9
decreased localization of amyloid-precursor protein (APP) in the trans-Golgi network 3 0 (TGN), and increased localization of APP in early endosomes, a site of APP cleavage 3 1 by the β secretase BACE1. Microglia, immune cells of the CNS, which play a role in AD 3 2 pathology also express SORL1. We therefore tested and found no effect of SORL1 3 3 depletion on endosome size or morphology in hiPSC-derived microglia, suggesting a 3 4
selective effect on neuronal endosomal trafficking. Finally, because BACE1 dependent 3 5
APP fragments can cause endosome enlargement, we treated SORL1 deficient hiPSC-3 6
derived neurons with BACE1 inhibitors and demonstrate that endosome enlargement 3 7
occurs independent of amyloidogenic APP fragments. Collectively, these findings clarify 3 8
where and how SORL1 links to AD. Moreover, our data, together with recent findings, 3 9
underscores how sporadic AD pathways that regulate endosomal trafficking, and 4 0
autosomal-dominant AD pathways that regulate APP cleavage, independently converge 4 1 on the defining cytopathology of AD. 4 2 4 3
Introduction: 4 4
Alzheimer's disease (AD) is the most common neurodegenerative disorder in the elderly 4 5
affecting nearly 40 million people worldwide [1] . Currently, there is no treatment that 4 6 alters disease progression. Recent therapeutic designs have focused on the main 4 7 neuropathologic hallmarks of AD, accumulations of amyloid beta (Aβ) in senile plaques 4 8
and abnormally phosphorylated tau protein in neurofibrillary tangles. The nearly 4 leading to complete loss of SorLA protein (SORL1 KO). (Supplemental Figure 1) . In 9 4
neurons differentiated from the SORL1 KO hiPSC lines, we quantified staining of 9 5 endogenous EEA1 and Rab5, (markers of early endosome morphology) using blinded, 9 6 unbiased confocal microscopy. We observed significantly increased fluorescence 9 7
intensity from EEA1 stained puncta (Figure 1A-B ) and Rab5 stained puncta 9 8
(Supplemental Figure 3) in SORL1 KO neurons. Western blot analysis showed no 9 9
change in total EEA1 protein between WT and SORL1 KO neurons (Supplemental 1 0 0 Figure 2 ), suggesting that the increased fluorescence intensity is due to enlarged or 1 0 1 fused early endosomes. We quantified endosome size and binned populations based 1 0 2 on > 0.5μm or <0.5 μm diameter distributions ( Figure 1C) . We observed significantly 1 0 3 more endosomes greater than or equal to 0.5 μm in in SORL1 KO neurons ( Figure 1C) , 1 0 4
and a statistically significant increase in the mean EEA1 puncta area over the 1 0 5 population of early endosomes as a whole (Figure 1D) . Interestingly, we also noticed 1 0 6 significantly enlarged endosomes in neural progenitor cells from the SORL1 KO lines 1 0 7 (Supplemental Figure 3 ) lines suggesting that loss of SORL1 impacts endosome 1 0 8 morphology early in the neural lineage, after hiPSCs are driven to neuroectoderm. 1 0 9
Finally, we also tested an shRNA against SORL1 in WT neurons and again observed 1 1 0 significantly enlarged endosomes (Supplemental Figure 3 ), suggesting that an acute 1 1 1 reduction of SORL1 also leads to this phenotype. 1 1 2 1 1 3
Enlarged early endosomes in the context of SORL1 depletion occur independent 1 1 4 of amyloidogenic APP processing. 1 1 5
Recent work has shown that neurons with introduced FAD mutations also show 1 1 6 enlarged endosome morphology that is FAD gene-dose dependent [26] . In Kwart et al.'s 1 1 7 study, endosome enlargement was dependent on β-secretase processing of APP. To 1 1 8
test whether amyloidogenic processing of APP was also contributing to early endosome 1 1 9 enlargement in the context of SORL1 loss, we treated SORL1 KO and isogenic WT 1 2 0
neurons with an inhibitor of BACE1 (BACE1i), effectively reducing both Aβ peptide 1 2 1 levels in our neurons ( Figure 2H) . Interestingly, in BACE1i treated neurons, we 1 2 2
observed an even stronger increase in mean EEA1 intensity (Figure 1 E-F ) and no 1 2 3 amelioration of early endosome enlargement (Figure 1 G-H) . There was no difference 1 2 4 in endosome size in WT cells treated with BACE1i as compared to DMSO treatment 1 2 5 (Figure 1 F) . This data suggests the mechanism by which loss of SORL1 expression 1 2 6
induces endosome enlargement is different from how FAD mutations impact the 1 2 7 endosomal network, and is independent of amyloidogenic APP processing. 1 2 8 1 2 9
Enlarged early endosomes in SORL1 deficient cells are present in hiPSC-derived 1 3 0 neurons, but not microglial-like cells. 1 3 1 AD-associated risk genes and their biological pathways may function differently 1 3 2 between unique central nervous system cell types. Indeed, recent work using hiPSC-1 3 3 derived, gene-edited cells demonstrates that the strongest AD genetic risk factor, APOE 1 3 4 ε4, impacts different cellular AD phenotypes in a cell type-specific manner [27, 28] . 1 3 5
Microglia, the innate immune cells of the CNS, also express SORL1[12] but the 1 3 6
functional role of SORL1 in microglia is undefined and functionality of the endocytic 1 3 7
network is likely very different in these highly phagocytic cells compared with neurons, 1 3 8
which are professional secretory cells. We differentiated SORL1 KO iPSCs to 1 3 9 microglial-like cells using a previously published protocol[29] (Supplemental Figure 4 ) 1 4 0 and analyzed endogenous EEA1 staining using similar protocols and analysis as for the 1 4 1 hiPSC-derived neurons. Surprisingly, we did not observe any differences in early 1 4 2 endosome fluorescence intensity (Figure 1 I-J) or size (Figure 1 K) A. SORL1 depletion results in APP accumulation in EEA1+ early endosomes. 3 4 9
Representative immunofluorescence images of wild-type and SORL1 KO neurons 3 5 0 stained with EEA1 (red), APP C-terminal antibody (green), MAP2 (red), and DAPI 3 5 1 (blue). Arrows indicate colocalization of EEA1+ puncta with APP and APP fragments. G. SORL1 KO neurons have higher levels of Aβ 1-40 and Aβ 1-42 peptides than WT cells, 3 7 3 indicated by asterisks (*). BACE1 inhibition significantly reduces these peptides in both 3 7 4
genotypes as compared to their DMSO controls, indicated by hashmarks (#). In the 3 7 5
presence of BACE inhibition SORL1 KO neurons still have increased levels of Aβ 1-40 3 7 6
and Aβ 1-42 peptides, indicated by asterisks (*). 3 7 7 3 7 8
H. Neither SORL1 KO nor BACE1 inhibition changes the ratio of Aβ 1-40 and Aβ 1-42 3 7 9
peptides. gRNA (underlined) was targeted to exon 6 in the SORL1 coding sequence. The light 3 9 0 blue shading, indicated by an arrowhead, indicates a synonymous SNP present in the 3 9 1 donor hiPSC line that differs from the reference genome. The two KO clones used in 3 9 2
this study showed and insertion (E1) and a deletion (E4) three bases upstream of the 3 9 3
PAM site that leads to a frameshift and premature stop codon. 3 9 4 3 9 5
B. Representative Western blots and quantitation show reduction of SORLA protein 3 9 6 levels to nearly zero in the KO hiPSCs, NPCs, and neurons. Quantification for all cell 3 9 7
types, n=6 biological replicates. All values represent mean +/-SD. All normally 3 9 8 distributed data were analyzed by two-tailed unpaired t-test *p<.05, **p<.01, ***p<.001, 3 9 9 ****p<.0001. Representative immunofluorescence images and Western blot of SORL1 KO and 4 2 7
isogenic wild-type microglial-like cells differentiated from hiPSCs. Microglia-like cells 4 2 8
show expression of microglial markers IBA1 and CX3CR1. Biosciences, San Jose, CA) at a concentration of 5μL/10 million cells. Following 5 0 4
antibody incubation, cells were washed with IMAG solution and incubated with anti-PE 5 0 5
magnetic beads (BD Biosciences, San Jose, CA) at a concentration of 25μL/10 million 5 0 6
cells. Bead-antibody complexes were pulled down using a rare earth magnet, 5 0 7
supernatants were selected, washed, and plated at an appropriate density. 5 0 8 5 0 9
Differentiation of iPSCs into microglia 5 1 0 SORL1 KO and WT iPSCs were differentiated into microglia as previously 5 1 1
described [29] . Briefly, iPSCs were plated in mTESR TM 1 medium (#05850; STEMCELL 5 1 2
Technologies) supplemented with ROCK Inhibitor (Y-27632; # A3008 ; Apex Bio) on 5 1 3
Matrigel (Growth factor reduced basement membrane matrix; # 356231; Corning) 5 1 4 coated 6 well plates (#657160; CELLSTAR) at a dilution of 1:30. To begin 5 1 5
hematopoietic progenitor differentiation, these cells were passaged to get a density of 5 1 6
~100 colonies (~150 cells per colony of iPSCs) per well of a 6 well plate. On day 0, 5 1 7 mTESR TM 1 medium was replaced with STEMdiff™ Hematopoietic Supplement A 5 1 8 medium from the STEMdiff™ Hematopoietic kit (# 05310; STEMCELL technologies). 5 1 9
On day 3, when colonies became flattened, medium was replaced with STEMdiff™ 5 2 0
Hematopoietic Supplement B medium from the STEMdiff™ Hematopoietic kit (# 05310; 5 2 1 STEMCELL technologies). Cells remained in this medium for 7 additional days. By day 5 2 2 10, non-adherent hematopoietic progenitor cells (HPCs) coming off from the flattened 5 2 3 colonies were harvested by removing medium. Any remaining HPCs/floating cells were 5 2 4
collected by gentle PBS washes. At this point, HPCs were either frozen using 5 2 5
Bambanker cell freezing medium (#BBH01; Bulldog-Bio) or plated at a density of 0.2M 5 2 6
cells per well of a Matrigel coated (1:60 dilution) 6 well plate in microglia differentiation 5 2 7 medium for 25 days. Microglia differentiation medium comprised of DMEM-F12 5 2 8 (#11039047; Thermo Fisher Scientific) , Insulin-transferrin-selenite (#41400045; Thermo 5 2 9
Fisher Scientific), B27 (# 17504-044; Thermo Fisher Scientific), N2 (# 17502-048; Scientific). On day 25, this medium was supplemented with CD200 (#C311; 5 3 5
Novoprotein) and CX3CL1 (#300-31; Peprotech) for maturation of microglia. Cells 5 3 6
remained in this medium for 3 days. On day 28, microglia differentiation was complete, 5 3 7
and these cells were plated in laminin (#L2020; Sigma) coated coverslips (12mm 5 3 8
diameter, #1760-012; cglifesciences) in a 24 well plate for immunocytochemistry with 5 3 9 appropriate antibodies. 5 4 0 Amyloid Beta measurements 5 4 1
Aβ peptides and phosphorylated tau were measured as previously described (Young 5 4 2 2015). Briefly, purified neurons were seeded at a density of 200,000 cells/well of a 96-5 4 3
well plate and maintained in culture for 5 days. Medium and lysates were harvested 5 4 4 from triplicate wells. To measure secreted Aβ peptides, media was run on an Aβ Triplex 5 4 5
ELISA plate (Meso Scale Discovery). 5 4 6 5 4 7
Immunocytochemistry 5 4 8
Purified neurons were seeded at a density of 500,000 cells per well of a 24-well plate on 5 4 9 glass coverslips coated with Matrigel. After 5 days in culture, cells were fixed in 4% 5 5 0 paraformaldehyde (PFA, Alfa Aesar, Reston, VA) for 15 minutes. Cells were incubated 5 5 1 in blocking buffer containing 2.5% bovine serum albumin and 0.1% Triton X-100 (Sigma 5 5 2
Aldrich, St Louis, MO) for 30 minutes at room temperature then incubated in a primary 5 5 3
antibody dilution in blocking buffer for 2 hours at room temperature. Cells were washed 5 5 4
3x with PBS + 0.1% Triton X-100 and incubated with a secondary antibody dilution in 5 5 5
blocking buffer for 1 hour at room temperature. Cells were washed 3x in PBS and 5 5 6 mounted on glass slides with ProLong Gold Antifade mountant (ThermoFisher, 5 5 7
Waltham, MA). The following primary antibodies were used: Ras-related protein Rab-5A 5 5 8
(RAB5A) at 1:500 (Synaptic Systems 108 011); early endosome antigen 1 (EEA1) at 5 5 9
1:500 (BD 610456); amyloid precursor protein (APP) at 1:250 (Abcam ab32136); 5 6 0 microtubule-associated protein 2 (Map2) at 1:1000 (Abcam ab92434); Nestin (NES) at 5 6 1 1:1000 (Santa Cruz Biotechnology sc23927); Trans-Golgi network integral membrane 5 6 2 protein (TGN38) at 1:250 (Santa Cruz sc-166594); Ras-related protein Rab-7a (Rab7) 5 6 3
at 1:1000 (Abcam ab50533); DAPI at 1 μg/mL final (Alfa Aesar). 5 6 4 5 6 5
Confocal Microscopy and Image Processing 5 6 6
All microscopy and image processing were performed under blinded conditions. 5 6 7
Confocal z-stacks were obtained using a Nikon A1R confocal microscope with x63 and 5 6 8
x100 plan apochromat oil immersion objectives. Image processing was performed using 5 6 9
ImageJ software. For endosome analysis, maximum intensity projections of confocal 5 7 0 stacks were generated, and background was subtracted using the rolling ball algorithm. 5 7 1
Endosome channels were enhanced using contrast limited adaptive histogram 5 7 2 equalization algorithms (CLAHE) and masked using cell body stains. Size and intensity 5 7 3 measurements were performed using CellProfiler software. Individual puncta were 5 7 4
identified using automated segmentation algorithms. Mean intensity of each puncta was 5 7 5 measured and has been presented as a mean value over all puncta per field. Similarly, 5 7 6
pixel area of each puncta was measured and has been presented as a mean area over 5 7 7
all puncta per field. For colocalization analysis, a minimum of 10 fields of confocal z-5 7 8
stacks were captured using the analyzed using the x100 plan apochromat oil immersion 5 7 9
objective. Median filtering was used to remove noise from images and manual 5 8 0
thresholding was applied to all images. The colocalization of APP with endocytic 5 8 1 markers was quantified using JACOP plugin in Image J and presented as Mander's 5 8 2 correlation coefficient. Purified neurons derived from SORL1 KO and WT iPSCs were plated on a matrigel 5 8 6 coated 96 well plate at a density of 2x10 5 cells per well. After 5 days, cells were treated 5 8 7 with either 25nM β -secretase inhibitor (BACEi; LY2886721; # HY-13240; 5 8 8
MedChemExpress) or DMSO (as a vehicle control) for 72h. All experiments were 5 8 9
performed after 72h of drug treatment. At this point, medium from DMSO or BACEi 5 9 0 treated neurons was harvested for quantification of Aβ-40 and Aβ-42 peptides secreted 5 9 1 by neurons by ELISA. Additionally, cell lysates were harvested for determining protein 5 9 2 levels of β -C terminal fragment (β-CTF) of Amyloid Precursor Protein (APP) by western 5 9 3 blot. 5 9 4 5 9 5
QUANTIFICATION AND STATISTICAL ANALYSIS 5 9 6
We used two independent clones of homozygous knockout cell lines and two 5 9 7
independent clones of isogenic wild-type cell lines (cells that underwent the 5 9 8
CRISPR/Cas9 transfection and sub-cloning process, but in which editing events did not 5 9 9
occur). Experimental data was tested for normal distributions. Normally distributed data 6 0 0
was analyzed using parametric ANOVA tests and non-normally distributed data was No datasets or code were generated during this study. The images and CellProfiler 6 0 7
pipelines used in this study are available from the corresponding author on request. 
